Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05787964 | Immunity to Infection in Healthy Participants and Participants With Cancer(SYS01) | unknown | — | 200 | University Hospital TuebingenOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06394622 | A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors | unknown | Phase 1 | 12 | Fudan UniversityOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT05804526 | A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours | unknown | Phase 1 / Phase 2 | 82 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05865925 | Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 78 | Luye Pharma Group Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05989724 | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 150 | Qurgen Inc.INDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06368960 | BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors(BM201-1001) | unknown | Phase 1 | 36 | InnoBM Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06363201 | Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours | unknown | N/A | 40 | Catalysis SLINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02266745 | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | unknown | Phase 2 | 109 | Promontory Therapeutics Inc.INDUSTRY | 2 | Apr 5, 2024 | clinicaltrials |
| NCT06348290 | Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects | unknown | Phase 1 | 72 | JemincareINDUSTRY | 0 | Apr 4, 2024 | clinicaltrials |
| NCT06247657 | A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours | unknown | Phase 1 | 66 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06339541 | The ACC Preclinical Research Platform for Precision Oncology(ACC Platform) | unknown | — | 250 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06326242 | What Unmet Need for the Patients?A Focus on the Social Determinants of Health in Phase 1 Clinical Trials | unknown | — | 100 | European Institute of OncologyOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT06139536 | Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients | unknown | Phase 1 | 210 | Bio-Thera SolutionsINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05103046 | First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 68 | 1200 Pharma, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05877664 | Study of ZG0895.HCl in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06237413 | A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours | unknown | Phase 1 / Phase 2 | 110 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06205082 | A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor | unknown | Phase 1 | 81 | LittDD Medicines LtdINDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05971862 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Oscotec Inc.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04934514 | Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 97 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04984668 | A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors | unknown | Phase 1 / Phase 2 | 216 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03863145 | Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors | unknown | Early Phase 1 | 90 | Cosmo Technologies LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05358379 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Feb 7, 2024 | clinicaltrials |
| NCT05367232 | A Study of ICP-033 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06240767 | Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils | unknown | Phase 1 | 18 | Wuxi People's HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05291182 | A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 40 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06037317 | A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors | unknown | Phase 1 | 38 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06232863 | A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer | unknown | Phase 1 | 24 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06239623 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | unknown | Phase 1 | 60 | JS InnoPharm, LLCINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT06223308 | A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 54 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05150405 | A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors | unknown | Phase 1 | 54 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05576961 | Safety and Efficacy of RX-af01 Combined With PD-1 Antibody | unknown | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05388487 | Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors | unknown | Phase 1 | 54 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04776005 | COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies(COVIDVAC OH) | unknown | — | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05164458 | Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies | unknown | Phase 1 | 320 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT04987112 | Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors | unknown | Phase 1 | 36 | CanWell Pharma Inc.INDUSTRY | 1 | Dec 22, 2023 | clinicaltrials |
| NCT06171971 | Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers(CS-PEDIA) | unknown | — | 230 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04407741 | Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06166472 | A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor | unknown | Phase 1 | 72 | AkesoINDUSTRY | 1 | Dec 12, 2023 | clinicaltrials |
| NCT04739293 | Study of ON 123300 in Patients With Advanced Cancer | unknown | Phase 1 | 36 | Traws Pharma, Inc.INDUSTRY | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05490264 | [68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors | unknown | Early Phase 1 | 20 | SmartNuclide BiopharmaINDUSTRY | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05322512 | Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors | unknown | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT05886868 | Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors | unknown | Phase 1 | 66 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 2 | Nov 29, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 9, 2024source: clinicaltrials